OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 24, 2020 -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today.

Oxford Immunotec Global is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Fourth quarter 2019 revenue of $18.1 million, an increase of 18% compared to the prior year periodFourth quarter 2019 gross margin of 78.3%, an increase of 410 basis points from.

Oxford Immunotec Global PLC (OXFD) (the “Company”), a global, high-growth diagnostics company, today announces two ground-breaking publications in Clinical Infectious Diseases (CID) on the performance of T-SPOT.CMV; a test for measuring the strength of a patient’s cellular immune response to Cytomegalovirus (CMV) in kidney and stem cell transplant. Increased response in the T-SPOT.CMV test is associated with protection against CMV infection. Application of the test raises the prospect of improved, individualized management of CMV infection risk in transplant recipients.

Peter Wrighton-Smith has been the CEO of Oxford Immunotec Global PLC (NASDAQ:OXFD) since 2002. This report will...

Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 45.45% and 4.80%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Oxford Immunotec (OXFD) delivered earnings and revenue surprises of -185.71% and -1.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

MEDNAX (MD) collaborates with Associated Pediatricians of Homestead to provide clinical services and expand presence in Florida.

OXFORD, United Kingdom and MARLBOROUGH, Mass., April 21, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (OXFD), a global, high-growth diagnostics company, today announced that it has successfully obtained re-registration of the T-SPOT.TB test in China. The re-registration was granted by the Chinese National Medical Products Administration (NMPA) on April 13, 2020 and, as is customary, the registration lasts until April 12, 2025 whereupon it will need to be renewed. As a Class III medical device, China’s Medical Device Registration Regulations and subsequent policies require that the company apply to the Center for Medical Device Evaluation (“CMDE”) of the National Medical Products Administration (“NMPA”) to renew its license for the T-SPOT.TB test every five years.

OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 27, 2020 -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced.

Oxford Immunotec Global PLC (OXFD) (the “Company”), a global, high-growth diagnostics company, today announced they are planning a new initiative to commemorate the coming World Tuberculosis Day, bring the benefits of the T-SPOT®.TB test to mainland China and assist with differentiating tuberculosis (TB) from other respiratory infections. Oxford Immunotec will donate tests approximately valued at CNY 3,000,000 to Chinese hospitals through a non-profit organization, Bethune Charitable Foundation, in support of their efforts to combat the outbreak of the coronavirus. Since its approval in the People’s Republic of China in 2010, T-SPOT.TB has been recognized for its high level of sensitivity and specificity across patient populations and has become a critical aid in the diagnosis of TB infection.

OXFORD, United Kingdom and MARLBOROUGH, Mass., April 29, 2020 -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today.

First quarter revenue of $13.9 million, a decrease of 6% compared to prior year period, due to the impact of COVID-19 in ChinaGross margins expanded 270bps to 74%Ended the.

Shares of Oxford Immunotec Global (NASDAQ:OXFD) remained unaffected at $11.76 after the company reported Q1 results.Quarterly Results Earnings per share were down 233.33% over the past year to ($0.20), which missed the estimate of ($0.15).Revenue of $13,911,000 less by 5.94% from the same period last year, which beat the estimate of $13,450,000.Outlook Earnings guidance hasn't been issued by the company for now.Q2 revenue expected between $5,000,000 and $6,000,000.How To Listen To The Conference Call Date: May 05, 2020View more earnings on OXFDTime: 10:01 PM ETWebcast URL: https://edge.media-server.com/mmc/p/g5rzprwmPrice Action 52-week high: $17.7752-week low: $8.37Price action over last quarter: down 10.98%Company Overview Oxford Immunotec Global PLC is a diagnostic company. It is focused on developing and commercializing proprietary tests for the management of underserved immune regulated conditions. Its products include T-spot TB, T-spot-CMV, T-spot PRT,T-cell extend etc. The company's research and development activities focus on Chronic infections, Transplantation, Autoimmune and Inflammatory disease, Immune oncology.See more from Benzinga * JELD-WEN Holding: Q1 Earnings Insights * Recap: Crestwood Equity Partners Q1 Earnings * Atkore International: Q2 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Investors can approximate the average market return by buying an index fund. While individual stocks can be big...

"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]

Oxford Immunotec Global PLC (OXFD) (the “Company”), a global, high-growth diagnostics company, today announces the release of the T-SPOT Discovery SARS-CoV-2 test kit. This research kit could make a significant contribution towards development of a new tool to manage the COVID-19 pandemic, which in turn could help to bring nations out of their current lockdowns in a faster, safer and more controlled manner. T-SPOT Discovery SARS-CoV-2 builds on Oxford Immunotec’s experience with TB diagnosis and the assessment of immune response to CMV in transplant patients, to apply the Company’s established, proprietary T-SPOT technology to the fight against COVID-19.

OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 06, 2020 -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr..

Q4 2019 Oxford Immunotec Global PLC Earnings Call

It is now my pleasure to turn the call over to Matt McLaughlin, Chief Financial Officer. Good morning and thank you for joining us to review Oxford Immunotec's financial results for the first quarter of 2020. Any statements made during this call that are not statements of historical or current facts are intended to be forward-looking statements pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.